Clay Siegall & How He’s Changing Cancer Research

 

When it comes to cancer research, there are numerous organization on the market today. Just about everyone has been affected by cancer in some form either directly or indirectly. This deadly disease can manifest within the body as well as in a number of vital organs. As of today, cancer research has come along way, but the fight isn’t over, rather it’s just getting started. Have you ever heard of a guy named Clay Siegall? If you haven’t then just know that this guy is in a class of his own and he has a huge list of accomplishments to back up all claims.

Clay Siegall is the Founder, CEO, and president of one of the leading cancer research organizations in the world. Seattle Genetics is it’s name and saving lives is it’s game. This Bothell, Washington based company has risen to the top of it’s class as it specializes in the development and commercialization of cancer breakthrough therapies. Clay Siegall is the captain of this ship and with his strong leadership, Seattle Genetics has become the go to organization of choice when it comes to producing the very best in cancer fighting treatments. Over the past five years, the company’s stock has tripled thanks to it’s powerful and effective medications. It’s flagship drug ADCETRIS, has become one of the most widely used cancer medications in the world today thanks to Clay Siegall. Siegall has enter the powerful medication into strategic licensing deals with some of the most prominent names in the world such as GlaxoSmithKline, Genentech, and Pfizer.

Having such a broad educational background, Clay Siegall has become the industry’s leading man. With a Ph.D in Genetics and a (BS) in Zoology, this brilliant minded man has more than enough knowledge, expertise, and capabilities. Siegall has also helped raise over $1 Billion dollars in private/public funding. With Clay Siegall steering this ship, the hopes of eradicating cancer is inevitable.

 

Leave a Reply

Your email address will not be published. Required fields are marked *